Sygnature Discovery

SEPTEMBER 11, 2024

Significant expertise in membrane protein production. Compound Screening Fragment Based Drug Discovery supported by Crystallography or SPR & MST. Covalent compound binding by mass spectrometry. Designed for end use. HEK, CHO, Insect, E.coli from mL to 25L scale. X-Ray Crystallography, Cryo-EM and NMR.

Science 52

Science Compound Screening Protein Expression RNA 52

Sygnature Discovery

SEPTEMBER 5, 2024

Individual labware capacities can be increased or decreased based on requirement Matrix 1.4ml tubes/ Fluid X 1mL Tubes 135,000 SBS microplates 6,500 Compound Handling: The Tecan Fluent liquid handler enhances productivity and precision through state-of-the-art automation.

Compound Screening 52

Compound Screening Production Drugs 52

Drug Target Review

NOVEMBER 1, 2023

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The ChEMBL-og

APRIL 16, 2024

A significant effort has been made to correctly map the drug form of the EMA data by manually inspecting different EMA sources of information, such as the Product Information (Annex I: Summary of Product Characteristics and Annex III: Labelling and Package Leaflet) and/or Assessment Report, where available. University of Dundee: T.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108